Yahoo Web Search

Search results

    • Small Business - Salisbury Post | Salisbury Post

      The Salisbury Post· 4 days ago

      Late-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with ...

    • Small Business - The Andalusia Star-News | The Andalusia Star-News

      The Andalusia Star-News· 5 days ago

      GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024

    • Cozen Cities - June 5, 2024 | JD Supra

      JD Supra· 1 day ago

      BALTIMORE — Visiting Tech Companies Want to Expand Baltimore Presence- The latest Techstars Equitech Accelerator brought several innovative...

    • Black chambers conduct DC fly-in

      The Valdosta Daily Times, Ga. via Yahoo Finance· 2 days ago

      Jun. 4—WASHINGTON, Dc. — Representatives from the Georgia Coalition of Black Chambers (GCBC), a coalition of Black Commerce Associations and Black business leaders across ...

    • Small Business - Cordele Dispatch | Cordele Dispatch

      Cordele Dispatch· 2 days ago

      Lykos Therapeutics Provides Update on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD PR Newswire SAN JOSE, Calif., June 4, 2024 SAN JOSE, Calif., June 4, 2024 /PRNewswire/ -- Lykos Therapeutics ("Lykos"), a company